As a leading innovation-driven Pharmaceutical company, CSL Behring is committed to playing a major role in improving the quality of life for patients with rare and serious disorders. This site gives you insights into CSL Behring, its worldwide subsidiaries, and related industry information. To facilitate the use of this site, we provide you with tailored information dependent upon the purpose of your respective visit, be it as a patient, healthcare professional, investor or prospective employee.
PLEASE NOTE THAT NO INFORMATION IN THIS SITE IS PROVIDED WITH THE INTENTION OF NOR SHOULD IT BE VIEWED AS GIVING MEDICAL ADVICE OR INSTRUCTION ON THE CORRECT USE OF PRODUCTS MANUFACTURED OR DISTRIBUTED BY CSL Behring.
CSL Behring offers the information on this Web site for general educational and informational purposes only. This information is not intended as a substitute for advice, treatment, or recommendations from health care professionals. It is important to follow the advice of your physician and other health care professionals regarding your individual medical and health care needs. Please consult with your physician or other health care professional before using any drug product discussed within this Web site. CSL Behring is not engaged in rendering medical advice or services.
Except for our site visitors' downloading of a single copy of this site for informational, non-commercial purposes, no content on this site is to be copied, downloaded, or stored for any other purpose, nor is such content to be disseminated to any party or for any purpose, without the express, written permission of CSL Behring. CSL Behring retains the right, at any time, without prior notice, and with or without cause, to restrict or terminate a visitor's use of or access to this site.
CSL BEHRING ENDEAVORS TO KEEP THIS SITE UP-TO-DATE. HOWEVER, THE CONTENT ON THIS SITE IS PROVIDED WITHOUT WARRANTY OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON-INFRINGEMENT. CONTENT ON THIS SITE IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. CSL BEHRING MAKES NO REPRESENTATIONS OR WARRANTIES REGARDING THIS SITE AND ITS CONTENT REGARDING ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY, OR THAT THE USE OF THIS SITE WILL BE UNINTERRUPTED OR ERROR-FREE. VISITORS ARE RESPONSIBLE FOR THE VERIFICATION OF ANY INFORMATION BEFORE ACTING IN RELIANCE UPON SUCH INFORMATION, AND USE OF THIS SITE IS AT THE SOLE RISK OF VISITORS TO IT. VISITORS ARE ALSO RESPONSIBLE FOR TAKING ALL PRECAUTIONS NECESSARY TO ENSURE THAT ANY CONTENT THAT IS OBTAINED IS VIRUS-FREE. TO THE EXTENT THAT APPLICABLE STATE LAW RESTRICTS OR LIMITS IMPLIED WARRANTIES, ONE OR MORE OF THE ABOVE LIMITATIONS MAY NOT APPLY IN PARTICULAR CASES.
CSL BEHRING SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DAMAGES, WHETHER DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL, ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE SITE AND ITS CONTENT, REGARDLESS OF WHETHER OR NOT CSL BEHRING HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION OF LIABILITY INCLUDES, BUT IS NOT LIMITED TO, ANY RELIANCE BY ANY PARTY ON ANY CONTENT THAT IS OBTAINED DIRECTLY OR INDIRECTLY THROUGH THE USE OF THIS SITE, AS WELL AS ANY DAMAGES THAT ARISE AS A RESULT OF VIRUSES, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE SITE, OR DELAYS, MISTAKES, OR OMISSIONS IN TRANSMISSIONS TO OR FROM THE VISITOR, WHETHER CAUSED BY THEFT, DESTRUCTION, NEGLIGENCE, WAR, TERRORISM, ACTS OF GOD, TELECOMMUNICATIONS FAILURE, OR ANY UNAUTHORIZED ACCESS TO THE SITE OR ITS INFORMATION. VISITORS USE THIS SITE AND ITS CONTENTS AT THEIR OWN RISK.
For the convenience of our visitors, CSL Behring provides links to other Web sites. However, certain links on this site lead to resources located on servers maintained by third parties over whom CSL Behring has no control. CSL Behring is not responsible for third party content or the consequences of one of our visitor's use thereof; consequently, access to and use of such sites is at the risk of visitors to such sites. Such links do not and should not imply CSL Behring's endorsement of material on any other site. CSL Behring expressly disclaims any liability with regard to access to such sites.
As a useful resource to our visitors this site may contain expert opinions. Information in this site identified as expert opinion, or accessed from this site by hyperlink, represents the opinions of these respective experts, which are not necessarily those of CSL Behring. Such experts are not employees of CSL Behring and do not receive any compensation from CSL Behring for the use of their opinions. CSL Behring does not endorse, and is not responsible for, the accuracy or completeness of any information or opinions set forth in such materials. Please note that expert advice reflects only the personal view of that expert — in no case shall it be regarded as the opinion or responsibility of CSL Behring.
CSL Behring provides information with respect to its global and local pharmaceutical business that might not be relevant to every visitor around the world. For example, trademarks used for certain products may differ from country to country. Furthermore, in some countries regulatory authorities may approve products for sale with different indications, dosages and restrictions. If CSL Behring's products, programs and services mentioned in this site are not available in your country, any such reference does not imply that CSL Behring intends to announce these products, programs or services in your country. Consult your local CSL Behring contact or your physician for further information as to the availability of our products in your country. Due to laws specific to different jurisdictions, we may not be able to provide all visitors with information on our prescription drugs. CSL Behring intends to disclose country-specific product information primarily to healthcare professionals and, only where permissible, to the general public.
In any forum for discussion on this site, CSL Behring expects the participants to observe common rules for communication, such as mutual respect for others. Visitors must not distribute or publish any offensive, abusive, indecent, defamatory or obscene material or any material that breaches a third party's intellectual property rights.
Please note that it is CSL Behring's policy to enforce its intellectual property rights to the utmost extent as set forth in applicable laws, including criminal sanctions. The trademarks, logos and service marks (collectively the "Trademarks") displayed on this site are Trademarks owned or licensed by CSL Behring. Nothing on this site should be construed as granting, by implication or otherwise, any license or right in or to the Trademarks without the express written permission of CSL Behring or, if not CSL Behring, the owner of the Trademark. In addition, any reproduction, retransmission, modification or use of this site's content for other than personal, non-commercial purposes requires the prior written consent of CSL Behring. The following copyright notice must appear on every copy of the contents of this site or a portion thereof: Copyright © 2023 CSL Behring.
This site contains press releases and other news regarding CSL Behring, which CSL Behring believed to be accurate as of the date that it was prepared and/or posted on this site. Nevertheless, CSL Behring hereby disclaims any obligation to update such press releases and other news, and/or the information contained therein. In no event should any information about companies, other than CSL Behring, be relied upon as having been provided by CSL Behring, nor does the appearance of such information about other companies on this site constitute an endorsement by CSL Behring of the accuracy or completeness of such information.
In some cases, visitors to this site may be required to register or to obtain a password prior to gaining access to certain provisions of the site or to certain services provided by the site. If so, it is the responsibility of the visitor to ensure that the confidentiality of the registration information and password is maintained. The visitor shall be responsible for all uses of such password, whether or not the visitor has authorized such use.
This Web site can be accessed from the United States and other countries worldwide. Since the laws of each State or country may differ, you agree that the statutes and laws of the Commonwealth of Pennsylvania, without regard to any principles of conflicts of law, will apply to all matters relating to the use of this site.
Last updated: 12/6/2010
Important Safety Information
WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS
Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving KCENTRA, and inform them of signs and symptoms of thromboembolic events. KCENTRA was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. KCENTRA might not be suitable for patients with thromboembolic events in the prior 3 months.
KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. Because KCENTRA contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).
Hypersensitivity reactions to KCENTRA may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.
In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving KCENTRA were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
KCENTRA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
KCENTRA®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. KCENTRA is for intravenous use only.
Please see full prescribing information for KCENTRA.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.